VEGF及其抑制剂Axitinib在非小细胞肺癌临床治疗中的应用

Application of VEGF and its inhibitor Axitinib in the treatment of non- small cell lung cancer

血管内皮生长因子(vascular endothelial growth factor,VEGF)是一种特异性极强的促血管生成因子,可促进新生血管及淋巴管的形成。在多种肿瘤(如肺癌、胃癌、结肠癌、肾癌等)中高表达,且与癌症的发生、发展及转移密切相关,为癌症的生化诊断及靶向治疗提供了研究方向。阿西替尼(Axitinib)是一种以酪氨酸激酶为靶向、抑制血管生成的新抗癌药。本文就VEGF及其抑制剂阿西替尼在非小细胞肺癌临床治疗中的应用进行简要综述。

Vascular endothelial growth factor（VEGF） is a kind of strong specific promote angiogenesis factor,which cart promote the formation of new blood vessels and lymphatic vessels, highly expressed in a variety of tumors （such as lung cancer, gastric cancer,colon cancer, kidney cancer, etc. ） ,and VEGF is closely related to the occurrence, devel- oplnent and metastasis of cancer. This provides a research direction for biochemical diagnosis of cancer and targeted therapy. Axitinib is a new kind of cancer drugs of tyrosine kinase as targeted and inhibit angiogenesis. This paper gives a brief review on the application of VEGF and its inhibitor Axitinib in the clinical treatment of non - small cell lung cancer.